Trial · NCT04679012
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
NCT04679012, Phase 2, Active not recruiting, Weill Medical College of Cornell University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation. Trials, record NCT04679012. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04679012
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
- NCT number
- NCT04679012
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Weill Medical College of Cornell University
- Conditions
- Richter Syndrome, Chronic Lymphocytic Leukemia
- Interventions
- Polatuzumab Vedotin, Rituximab, Etoposide, Prednisone, Cyclophosphamide, Hydroxydaunomycin
- First posted
- 2020-12-22
- Last updated
- 2026-09-25
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete metabolic remission/complete remission (CMR/CR) rate of subjects at end of treatment (EOT) | 19 weeks | Percentage of subjects who achieve CMR/CR on study. |
| Secondary | Safety of polatuzumab vedotin plus infusional chemoimmunotherapy (CIT) containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin in patients with newly diagnosed Richter's Transformation. | 1.5 years | Percentage of subjects who experience 1 or more adverse events. |
| Secondary | Overall response rate (ORR) | 3 years | Rate of subjects who achieve a partial or complete response. |
| Secondary | Progression free survival (PFS) | 3 years | Measured from time of first study drug administration to objective or symptomatic progression or death. |
| Secondary | Overall survival (OS) | 3 years | Measured from time of first study drug administration to death from any cause. |
| Secondary | Allogeneic transplantation rate in eligible patients | 3 years | Percentage of eligible patients able to get allogeneic stem cell transplant. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04679012
GET https://conductscience.org/api/trials/v1/NCT04679012/registered